Sep. 29, 2009 (Business Wire) -- Rosetta Genomics, Ltd. (NASDAQ:ROSG) a leading developer of microRNA-based molecular diagnostics, announced that management will present a corporate update at the 2009 Maxim Group Growth Conference today, Tuesday, September 29, 2009 at 02:30 p.m., (Eastern Time) at the Grand Hyatt Hotel in New York City.
A live webcast of the presentation will be available by going to the investor relations section of www.rosettagenomics.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 90 days.
About Rosetta Genomics
Rosetta Genomics (Nasdaq:ROSG) is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets, and miRview™ meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of Wall Street Journal’s Technology Innovation Awards in the medical/biotech category.
Forward-Looking Statements
Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the development of early detection cancer screening products, including a non-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2008 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
